Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

30 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Enabling next-generation engineered TCR-T therapies based on high-throughput TCR discovery from diagnostic tumor biopsies.
Kuilman T, Schrikkema DS, Gadiot J, Gomez-Eerland R, Bies L, Walker J, Spaapen RM, Kok H, Houg D, Viyacheva M, Claassen YB, Saornil M, Krijgsman O, Stringer B, Ding H, Geleijnse A, Meinema AC, Weissbrich B, Lancee M, Engele CG, Sabatino M, Chen PL, Tsai KY, Mulé JJ, Sondak VK, van den Bulk J, de Miranda NF, Jedema I, Haanen JG, van Heijst JWJ, Schumacher TN, Linnemann C, Bendle GM. Kuilman T, et al. Nat Commun. 2025 Jan 14;16(1):649. doi: 10.1038/s41467-024-55420-6. Nat Commun. 2025. PMID: 39809767 Free article.
An adverse tumor-protective effect of IDO1 inhibition.
Kenski JCN, Huang X, Vredevoogd DW, de Bruijn B, Traets JJH, Ibáñez-Molero S, Schieven SM, van Vliet A, Krijgsman O, Kuilman T, Pozniak J, Loayza-Puch F, Terry AM, Müller J, Logtenberg MEW, de Bruijn M, Levy P, Körner PR, Goding CR, Schumacher TN, Marine JC, Agami R, Peeper DS. Kenski JCN, et al. Among authors: kuilman t. Cell Rep Med. 2023 Feb 21;4(2):100941. doi: 10.1016/j.xcrm.2023.100941. Cell Rep Med. 2023. PMID: 36812891 Free PMC article.
SERPINB9 is commonly amplified and high expression in cancer cells correlates with poor immune checkpoint blockade response.
Ibáñez-Molero S, van Vliet A, Pozniak J, Hummelink K, Terry AM, Monkhorst K, Sanders J, Hofland I, Landeloos E, Van Herck Y, Bechter O, Kuilman T, Zhong W, Marine JC, Wessels L, Peeper DS. Ibáñez-Molero S, et al. Among authors: kuilman t. Oncoimmunology. 2022 Nov 29;11(1):2139074. doi: 10.1080/2162402X.2022.2139074. eCollection 2022. Oncoimmunology. 2022. PMID: 36465485 Free PMC article.
RNF31 inhibition sensitizes tumors to bystander killing by innate and adaptive immune cells.
Zhang Z, Kong X, Ligtenberg MA, van Hal-van Veen SE, Visser NL, de Bruijn B, Stecker K, van der Helm PW, Kuilman T, Hoefsmit EP, Vredevoogd DW, Apriamashvili G, Baars B, Voest EE, Klarenbeek S, Altelaar M, Peeper DS. Zhang Z, et al. Among authors: kuilman t. Cell Rep Med. 2022 Jun 21;3(6):100655. doi: 10.1016/j.xcrm.2022.100655. Epub 2022 Jun 9. Cell Rep Med. 2022. PMID: 35688159 Free PMC article.
Predictive Immune-Checkpoint Blockade Classifiers Identify Tumors Responding to Inhibition of PD-1 and/or CTLA-4.
Krijgsman O, Kemper K, Boshuizen J, Vredevoogd DW, Rozeman EA, Ibanez Molero S, de Bruijn B, Cornelissen-Steijger P, Shahrabi A, Del Castillo Velasco-Herrera M, Song JY, Ligtenberg MA, Kluin RJC, Kuilman T, Ross-Macdonald P, Haanen JBAG, Adams DJ, Blank CU, Peeper DS. Krijgsman O, et al. Among authors: kuilman t. Clin Cancer Res. 2021 Oct 1;27(19):5389-5400. doi: 10.1158/1078-0432.CCR-20-4218. Clin Cancer Res. 2021. PMID: 34230026
Augmenting Immunotherapy Impact by Lowering Tumor TNF Cytotoxicity Threshold.
Vredevoogd DW, Kuilman T, Ligtenberg MA, Boshuizen J, Stecker KE, de Bruijn B, Krijgsman O, Huang X, Kenski JCN, Lacroix R, Mezzadra R, Gomez-Eerland R, Yildiz M, Dagidir I, Apriamashvili G, Zandhuis N, van der Noort V, Visser NL, Blank CU, Altelaar M, Schumacher TN, Peeper DS. Vredevoogd DW, et al. Among authors: kuilman t. Cell. 2020 Jan 23;180(2):404-405. doi: 10.1016/j.cell.2020.01.005. Cell. 2020. PMID: 31978349 Free article. No abstract available.
Augmenting Immunotherapy Impact by Lowering Tumor TNF Cytotoxicity Threshold.
Vredevoogd DW, Kuilman T, Ligtenberg MA, Boshuizen J, Stecker KE, de Bruijn B, Krijgsman O, Huang X, Kenski JCN, Lacroix R, Mezzadra R, Gomez-Eerland R, Yildiz M, Dagidir I, Apriamashvili G, Zandhuis N, van der Noort V, Visser NL, Blank CU, Altelaar M, Schumacher TN, Peeper DS. Vredevoogd DW, et al. Among authors: kuilman t. Cell. 2019 Jul 25;178(3):585-599.e15. doi: 10.1016/j.cell.2019.06.014. Epub 2019 Jul 11. Cell. 2019. PMID: 31303383 Free article.
Absence of PD-L1 expression on tumor cells in the context of an activated immune infiltrate may indicate impaired IFNγ signaling in non-small cell lung cancer.
Theelen WSME, Kuilman T, Schulze K, Zou W, Krijgsman O, Peters DDGC, Cornelissen S, Monkhorst K, Sarma P, Sumiyoshi T, Amler LC, Willems SM, Blaauwgeers JLG, van Noesel CJM, Peeper DS, van den Heuvel MM, Kowanetz M. Theelen WSME, et al. Among authors: kuilman t. PLoS One. 2019 May 24;14(5):e0216864. doi: 10.1371/journal.pone.0216864. eCollection 2019. PLoS One. 2019. PMID: 31125352 Free PMC article.
30 results